15
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T13175 | TNF-α-IN-1 | TNF | |
TNF-α-IN-1 is a TNF-α inhibitor. | |||
T3927 | Phellopterin | GABA Receptor | |
Phellopterin is a partial agonist of the central benzodiazepine receptors in vitro. Phellopterin shows a cytotoxic effect on RAW264.7 cell at the concentration from 40 to 400 μM. Phellopterin reduce TNF-alpha-induced VCA... | |||
T4S0795 | Berberrubine chloride | 9-Berberoline Chloride,Beroline,Beroline Chloride,Berberrubine,9-Berberoline | IL Receptor |
1. Berberrubine chloride (9-Berberoline Chloride) has antitumor activity. 2. Berberrubine has antidiabetic activity. 3. Berberrubine dose-dependently inhibits IL-8 and MCP-1 protein levels in the media and mRNA expressio... | |||
T10865 | Cot inhibitor-1 | TNF , MAPK | |
Cot inhibitor-1 is a selective inhibitor of Cot protein kinase (also known as Tpl2 or MAP3K8) (IC50 at 28 nM). Cot inhibitor-1 inhibited TNF-alpha production in human whole blood with IC50 of 5.7 nM. Cot is involved in a... | |||
T6S1256 | Ruscogenin | NOS , NF-κB , NOD-like Receptor (NLR) | |
1. Ruscogenin has anti-inflammatory activity, suppressed zymosan A-evoked peritoneal total leukocyte migration in mice in a dose-dependent manner, 2. Ruscogenin inhibited adhesion of leukocytes to a human umbilical vein ... | |||
T24816 | SP-100030 | SP100030,SP 100030 | NF-κB |
SP-100030 is a dual inhibitor of NF-κB and activator protein-1 (AP-1), demonstrating potent inhibition with IC50 values of 50 nM for both. It effectively reduces the production of IL-2, IL-8, and TNF-alpha in Jurkat and ... | |||
T81606 | Onercept | ||
Onercept, a recombinant soluble form of the human tumor necrosis factor-alpha (TNF-α) p55 receptor, is utilized in the study of Crohn's disease [1]. | |||
T36097 | TNF-α-IN-2 | ||
TNF-α-IN-2 is a highly potent and orally bioavailable inhibitor of tumor necrosis factor alpha (TNFα), exhibiting an IC50 of 25 nM in the HTRF assay. It exerts its inhibitory effects by inducing conformational changes in... | |||
T78548 | 3-Hydroxyxanthone | 3-Hydroxy-xanthen-9-one | Integrin |
3-Hydroxyxanthone (3-Hydroxy-xanthen-9-one), a xanthone derivative, exhibits inhibitory effects on NADPH-catalyzed lipid peroxidation in human umbilical vein endothelial cells (HUVECs) and suppresses TNF-alpha-induced IC... | |||
T81838 | Mca-(endo-1a-Dap(Dnp))-TNF-Alpha (-5 to +6) amide (human) | ||
Mca-(endo-1a-Dap(Dnp))-TNF-Alpha (-5 to +6) amide (human) is a peptide utilized as a fluorescence resonance energy transfer (FRET) based substrate for proteolytic activity assays, wherein the cleavage-induced change in f... | |||
T72687 | Keap1-Nrf2-IN-11 | ||
Keap1-Nrf2-IN-11 (Compound 6k), a potent Keap1-Nrf2 inhibitor, exhibits a dissociation constant (KD) of 0.21 nM. It hampers the production of reactive oxygen species (ROS) and nitric oxide (NO), as well as the expression... | |||
T76963 | Certolizumab pegol | ||
Certolizumab pegol (Certolizumab) is a recombinant, humanized monoclonal antibody fragment that has been modified with polyethylene glycol (PEG), which selectively targets and neutralizes tumor necrosis factor-alpha (TNF... | |||
T78434 | Mca-(endo-1a-Dap(Dnp))-TNF-Alpha (-5 to +6) amide (human) TFA | ||
Mca-(endo-1α-Dap(Dnp))-TNF-α(-5 to +6) amide (human) TFA is a peptide that functions as a fluorescence resonance energy transfer (FRET)-based substrate, with its activity determined by the change in fluorescence intensit... | |||
TN5011 | Shizukaol B | ERK , IL Receptor , p38 MAPK , TNF , NOS , NF-κB , COX , HIV Protease , DNA/RNA Synthesis , Prostaglandin Receptor , JNK | |
Shizukaol B exerts anti-inflammatory effects in LPS-activated microglia partly by modulating JNK-AP-1 signaling pathway; it also shows significant anti-neuroinflammatory effects by inhibiting nitric-oxide (NO) production... | |||
T36618 | Rupatadine | ||
Rupatadine (UR-12592) is a potent dual PAF/H1 antagonist with Ki of 0.55/0.1 uM(rabbit platelet membranes/guinea pig cerebellum membranes).IC50 value:Target: PAF/H1 antagonistin vitro: Rupatadine competitively inhibited ... |